NCT06307925

A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

Name: Clinical Trial NCT06307925
Creator: HC Biopharma Inc.
Keywords: Advanced Solid Tumor, HC010, Phase 1, drug, clinical trial, China

A Phase I Open-label, Multi-center, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors

HC Biopharma Inc.·Phase 1·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Advanced Solid Tumor
Drug/Device/Intervention: HC010
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: HC Biopharma Inc.
Location: Guangzhou, China

Timeline & enrollment

Phase: Phase 1
Start date: Mar 27, 2024
End date: Dec 31, 2025
Enrollment: 122 participants

Primary outcome

Incidence of dose-limiting toxicity,Adverse events,serious adverse events,Maximum Tolerated Dose,Recommended Dose for Phase II Clinical Studies

Summary

This clinical trial is a multicenter, open, single-arm, non-randomized, dose-escalation and dose-expansion, phase I clinical study in patients with advanced recurrent or metastatic solid tumors.The goal of this study is to evaluate the safety and tolerability of HC010 monotherapy in patients with advanced solid tumors.

ICD-10 classifications

Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06307925
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06307925 through Pure Global AI's free database. This Phase 1 trial is sponsored by HC Biopharma Inc. and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 122 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.